1. Home
  2. NKTR vs PTMN Comparison

NKTR vs PTMN Comparison

Compare NKTR & PTMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKTR
  • PTMN
  • Stock Information
  • Founded
  • NKTR 1990
  • PTMN 2006
  • Country
  • NKTR United States
  • PTMN United States
  • Employees
  • NKTR N/A
  • PTMN N/A
  • Industry
  • NKTR Biotechnology: Pharmaceutical Preparations
  • PTMN Finance: Consumer Services
  • Sector
  • NKTR Health Care
  • PTMN Finance
  • Exchange
  • NKTR Nasdaq
  • PTMN Nasdaq
  • Market Cap
  • NKTR 160.4M
  • PTMN 142.6M
  • IPO Year
  • NKTR 1994
  • PTMN N/A
  • Fundamental
  • Price
  • NKTR $0.74
  • PTMN $14.37
  • Analyst Decision
  • NKTR Strong Buy
  • PTMN Hold
  • Analyst Count
  • NKTR 5
  • PTMN 1
  • Target Price
  • NKTR $5.50
  • PTMN $16.00
  • AVG Volume (30 Days)
  • NKTR 1.4M
  • PTMN 52.0K
  • Earning Date
  • NKTR 03-12-2025
  • PTMN 03-13-2025
  • Dividend Yield
  • NKTR N/A
  • PTMN 15.04%
  • EPS Growth
  • NKTR N/A
  • PTMN N/A
  • EPS
  • NKTR N/A
  • PTMN N/A
  • Revenue
  • NKTR $98,427,000.00
  • PTMN $62,432,000.00
  • Revenue This Year
  • NKTR N/A
  • PTMN $6.34
  • Revenue Next Year
  • NKTR N/A
  • PTMN N/A
  • P/E Ratio
  • NKTR N/A
  • PTMN N/A
  • Revenue Growth
  • NKTR 9.21
  • PTMN N/A
  • 52 Week Low
  • NKTR $0.65
  • PTMN $14.30
  • 52 Week High
  • NKTR $1.93
  • PTMN $20.84
  • Technical
  • Relative Strength Index (RSI)
  • NKTR 36.32
  • PTMN 18.92
  • Support Level
  • NKTR $0.84
  • PTMN $14.30
  • Resistance Level
  • NKTR $0.92
  • PTMN $15.69
  • Average True Range (ATR)
  • NKTR 0.08
  • PTMN 0.43
  • MACD
  • NKTR -0.01
  • PTMN -0.17
  • Stochastic Oscillator
  • NKTR 0.40
  • PTMN 2.35

About NKTR Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

About PTMN Portman Ridge Finance Corporation

Portman Ridge Finance Corp Inc is a non-diversified closed-end investment company. The company originates, structures, and invests in secured term loans, bonds or notes, and mezzanine debt primarily in privately-held middle market companies but may also invest in other investments such as loans to publicly traded companies, high-yield bonds, and distressed debt securities. The company's investment objective in the Debt securities portfolio is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt, and selected equity investments in privately-held middle market companies.

Share on Social Networks: